Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Emilio Sanseviero Clear advanced filters

  • The ATR inhibitor ceralasertib has shown clinical activity in combination with immune-checkpoint inhibitors in several cancer types. Here the authors report the anti-tumor activity and the immunomodulatory changes, dependent on up-regulation of type I interferon pathway, following intermittent ATR inhibition in preclinical cancer models.

    • Elizabeth L. Hardaker
    • Emilio Sanseviero
    • Simon T. Barry
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-20

  • The role of type I interferon signalling in the control of myeloid derived suppressor cells (MDSC) activity remains controversial. Here the authors show that downregulation of type I interferon receptor is observed in MDSC from cancer patients and tumor-bearing mice and is required for the activation of their immune suppressive properties.

    • Kevin Alicea-Torres
    • Emilio Sanseviero
    • Dmitry I. Gabrilovich
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-13

  • This Review from Gabrilovich and colleagues discusses our current understanding of the development and functions of myeloid-derived suppressor cells (MDSCs). Recent work has identified unique metabolic properties and gene expression patterns in MDSCs that could help in the development of new therapies for cancer and autoimmunity.

    • Filippo Veglia
    • Emilio Sanseviero
    • Dmitry I. Gabrilovich
    Reviews
    Nature Reviews Immunology
    Volume: 21, P: 485-498